Protein ubiquitination is a multi-functional post-translational modification that affects all cellular processes. Its versatility arises from architecturally complex polyubiquitin chains, in which individual ubiquitin moieties may be ubiquitinated on one or multiple residues, and/or modified by phosphorylation and acetylation 1-3 . Advances in mass spectrometry have enabled the mapping of individual ubiquitin modifications that generate the ubiquitin code; however, the architecture of polyubiquitin signals has remained largely inaccessible. Here we introduce Ub-clipping as a methodology by which to understand polyubiquitin signals and architectures. Ub-clipping uses an engineered viral protease, Lb pro * , to incompletely remove ubiquitin from substrates and leave the signature C-terminal GlyGly dipeptide attached to the modified residue; this simplifies the direct assessment of protein ubiquitination on substrates and within polyubiquitin. Monoubiquitin generated by Lb pro * retains GlyGly-modified residues, enabling the quantification of multiply GlyGly-modified branch-point ubiquitin. Notably, we find that a large amount (10-20%) of ubiquitin in polymers seems to exist as branched chains. Moreover, Ub-clipping enables the assessment of co-existing ubiquitin modifications. The analysis of depolarized mitochondria reveals that PINK1/parkin-mediated mitophagy predominantly exploits mono-and short-chain polyubiquitin, in which phosphorylated ubiquitin moieties are not further modified. Ub-clipping can therefore provide insight into the combinatorial complexity and architecture of the ubiquitin code.
, on residues on which ubiquitin had been attached. Antibodies that detect GlyGlymodified Lys residues enrich these peptides, enabling the mapping of tens of thousands of ubiquitination sites 5, 6 . Moreover, labelled ubiquitin-derived GlyGly-modified peptides facilitate absolute quantification (AQUA) techniques to quantify polyubiquitin linkage composition [7] [8] [9] , ubiquitin phosphorylation and acetylation [10] [11] [12] [13] . A disadvantage of tryptic digestion is the loss of architectural information on polyubiquitin chains. Limited trypsinolysis 14, 15 , ubiquitin chain restriction analysis 16 and an antibody recognizing co-existing Lys11/Lys48 linkages present in branched chains 17 can provide some insights into chain architecture 18 . However, such approaches require experimental optimization, specialist expertise, or are limited to particular chain combinations. As a result, the combinatorial context of co-existing ubiquitin modifications (for example, double-or triple-ubiquitinated ubiquitin species, or phosphorylation in particular chain contexts) has remained largely inaccessible.
We recently demonstrated that the leader protease (Lb pro ) of footand-mouth disease virus hydrolyses the ubiquitin-like modifier ISG15 at the peptide bond between Arg155 and the C-terminal Gly156-Gly157 motif, generating GlyGly-modified proteins and incapacitating ISG15 19 . At higher enzyme concentrations, Lb pro targets all types of diubiquitin (Fig. 1a) , cleaving each ubiquitin moiety after Arg74 (Fig. 1b, Extended Data Fig. 1a ) and generating two products: a truncated ubiquitin that spans residues 1-74 (8,450.6 Da) originating from the distal moiety, and a GlyGly-modified ubiquitin 1-74 (8,564.6 Da) (Fig. 1c) . Prolonged incubation does not lead to further proteolysis (Extended Data Fig. 1b) .
The modelling of ubiquitin onto ISG15 from our recent structure 19 of the Lb pro -ISG15 complex (Extended Data Fig. 1c ) rationalizes the ubiquitin cleavage site 20 and enables enzyme engineering. We then generated Lb pro with a leucine-to-tryptophan mutation at residue 102-denoted Lb pro (L102W) or Lb pro * -which had improved capability to target all types of diubiquitin, improved catalytic efficiency, and a greater ability to cleave branched triubiquitin (Extended Data Fig. 2 ). Subsequently we refer to either variant as Lb pro , but note that Lb pro * is the preferred enzyme for studying ubiquitination owing to its superior properties.
Lb pro converts ubiquitinated proteins into GlyGly-modified proteins (Fig. 1d ). This unusual 'clippase' activity collapses complex polyubiquitin samples to GlyGly-modified monoubiquitin species that can be further analysed, for example by AQUA methods. In vitro analysis of various E3 ligase systems by SDS-PAGE purification and AQUA MS revealed the expected linkage compositions, with reduced background from non-ubiquitin peptides (Extended Data Fig. 3) .
Notably, the intact mass of the generated monoubiquitin yields additional insights into chain architecture (Fig. 2a) . In RING-ligase reactions performed with the E2 enzyme UBE2D3, around 10% of ubiquitin had been modified with two, three or even four GlyGly groups (Fig. 2b , c, Extended Data Fig. 4 ). Branched ubiquitin species were not a result of incomplete cleavage (that is, GlyGly-modified ubiquitin with an intact C terminus), because the most abundant transition ions of an isolated di-GlyGly-modified ubiquitin species comprised a 'clipped' C terminus (Extended Data Fig. 4e ). UBE2D family enzymes are promiscuous with respect to their target Lys 21 . Ub-clipping reveals that the promiscuity of UBE2D3 can generate highly branched, tree-like polyubiquitin architectures.
One complication from these studies is that unassembled monoubiquitin in the reaction artificially increases the apparent amount of unmodified ubiquitin, skewing the results of chain composition. To counteract this, we used tandem ubiquitin-binding entity (TUBE) pull-down assays 22 to remove free monoubiquitin before treatment with Lb pro , thereby enabling estimation of the average chain length (Extended Data Fig. 5 ).
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The advantages and the robustness of Lb pro -mediated Ub-clipping became more apparent when applied to complex mixtures such as cell lysates, opening new possibilities for analysis of the ubiquitome. Lb pro was active in 1 M urea, which inhibits assembly and cleavage of polyubiquitinated proteins by endogenous ligases and deubiquitinases (Fig. 3a, Extended Data Fig. 6a-c) . Treatment of cell lysates with Lb pro therefore collapses high-molecular weight ubiquitin conjugates, generating a monoubiquitin species (Fig. 3a, Extended Data Fig. 6a, b) . In-gel trypsin digestion and AQUA MS of the single 8-kDa monoubiquitin product revealed the global linkage composition of the entire cell lysate (Fig. 3a) , with results identical to those of the whole-cell lysate tryptic digests 6, 23 . Treatment of cell lysates with Lb pro generates GlyGly-modified proteins, which can be visualized using the anti-GlyGly antibody 5, 6, 19, 24 ( Fig. 3b) . Previously modified proteins that appear as high-molecular-mass smears are collapsed to more discrete bands close to their original size (Fig. 3b) . This may prove useful for global ubiquitination site analysis and for directed ubiquitination studies of specific proteins.
To study ubiquitin chain branching in cells, we purified the monoubiquitin band (Extended Data Fig. 6d-f ). Samples showed similar ubiquitin linkage compositions as those previously reported 23, 25 (Extended Data Fig. 6g ) and minimal background (Extended Data  Fig. 6h ). Next, intact MS analysis was used to derive the relative amounts of differently modified ubiquitin species. Globally, most ubiquitin was unmodified; the pool consists of free ubiquitin, monoubiquitinated proteins, and terminal ubiquitin moieties in chains 25 . In addition, as reported previously 25 , around 10% of ubiquitin was mono-GlyGly-modified (Fig. 3c, d) . Notably, low levels of di-GlyGlyand even tri-GlyGly-modified ubiquitin were also detected (Fig. 3c, d , Extended Data Fig. 7a) . We confirmed the removal of the GlyGly C terminus from branched ubiquitin species using fragmentation analysis (Extended Data Fig. 7b-d) .
In whole-cell lysates, branch-point ubiquitin accounted for approximately 0.5% of the total ubiquitin in three cell lines analysed (Fig. 3d) . Next, the amount of branching in polyubiquitin was assessed using TUBE pull-down assays. The overall linkage composition of TUBEenriched polyubiquitin was similar to that from whole-cell lysates ( Fig. 3e ; compare with Extended Data Fig. 6g ). Intact MS analysis and quantification by peak integration (Extended Data Fig. 8 ; also see Methods) revealed that around 4-7% of all ubiquitin in TUBE pulldown assays had two GlyGly modifications (Fig. 3f) . This suggests that a substantial fraction (around 10-20%) of ubiquitin in polymers exists in the context of a branched chain, which is consistent with data from limited trypsinolysis experiments 18 (Extended Data Fig. 8e ). It is becoming increasingly clear that cells use specific contextdependent ubiquitin signals for particular tasks; a key example of this is PINK1/parkin-driven mitophagy, the organized destruction of mitochondria by means of autophagy 26, 27 . In this process, PINK1 generates Ser65-phosphorylated ubiquitin (phosphoubiquitin); this leads to activation of the E3-ligase parkin that further ubiquitinates damaged mitochondria, and the subsequent initiation of mitophagy 26, 27 . Whereas the substrates and linkage composition of parkin-directed ubiquitination events have been studied in great detail 10, [28] [29] [30] [31] , less is known about the architecture of the mitophagy signal.
We used Ub-clipping to study mitophagy. Lb pro was able to hydrolyse phosphoubiquitin chains (Extended Data Fig. 9a, b) , and TUBE-based in vitro analysis of activated parkin yielded the expected polyubiquitin linkage composition with Lys6-(38-43%), Lys11-(11-12%), Lys48-(27-33%) and Lys63-linkages (16%) 10, 30 . Notably, intact mass analysis showed that parkin produces predominantly short chains (with a ratio between GlyGly-modified and unmodified ubiquitin of approximately 1:2) that also include branched ubiquitin species (Extended Data Fig. 9c-e) . Ub-clipping also revealed multiple GlyGly modifications on the E2 enzyme UBE2L3 (Extended Data Fig. 9f ), highlighting the utility of this method for characterizing substrate ubiquitination.
In cells, the depolarization of mitochondria triggers parkin activity 26, 27 . This activity can be controlled using HeLa cell lines that express either wild-type parkin or dysfunctional parkin mutants (with C431S or S65A mutations) 10, 29 . Detailed proteomic studies have characterized this experimental system 10, 29, 32 . TUBE pull-down assays and Ub-clipping of enriched polyubiquitin (Fig. 4a, b , Extended Data Fig. 10a, b) revealed the expected changes in the global ubiquitome and the appearance of phosphoubiquitin in response to depolarizing agents (Extended Data Fig. 10c ). Intact ubiquitin analysis revealed an isotopic distribution corresponding to unmodified phosphoubiquitin (Fig. 4c) . The expression of wild-type parkin did not lead to global changes in architecture composition of enriched polyubiquitin; however, phosphoubiquitin-in a species that was primarily not GlyGly-modified (that is, mono-or endcap ubiquitin)-was found to account for around 7% of the total ubiquitin (Fig. 4d, Extended Data Fig. 10d) .
These results were corroborated in mitochondrial preparations. Treatment of mitochondrial fractions that enrich (phospho)ubiquitinated integral membrane proteins 33 with sodium carbonate alleviated the requirement for TUBE pull-down, as it depleted free ubiquitin from the samples (Fig. 4e, Extended Data Fig. 10e ). Under these conditions and as expected, mitochondrial depolarization and concurrent parkin activity led to an increase in the amount of ubiquitin on mitochondria, and to changes in polyubiquitin linkage composition 10 ( Fig. 4f, g ). Intact mass analysis revealed a large amount of phosphoubiquitin (around 10% with parkin(C431S), and around 33% with wild-type parkin), the vast majority of which (8% and 27%, respectively) was not further modified (Fig. 4h, Extended Data Fig. 10f, g ). In both cell lines, approximately 30% of the ubiquitin had a single GlyGly-modification (Fig. 4h) .
These data, together with recent data on ubiquitination siteoccupancy during mitophagy 32 , enable modelling of the Letter reSeArCH parkin-assembled ubiquitin coat on mitochondria (Extended Data  Fig. 10h ). First, a large relative amount of non-ubiquitinated ubiquitin indicates predominantly monoubiquitination and short chains. Second, the amounts of monoubiquitin and single-GlyGly-modified ubiquitin are similar in cells expressing parkin(C431S) and those expressing wild-type parkin; this indicates that, under conditions of chemical mitochondrial depolarization, the overall ubiquitin chain length is not substantially altered upon the expression of active parkin. Third, most phosphoubiquitin exists at the tip of chains; this is consistent with previous findings that parkin attaches only unphosphorylated ubiquitin 11 , and that PINK1 prefers to phosphorylate distal ubiquitin moieties 34 . Together with the observed overall increase of mitochondrial ubiquitin, these results indicate that PINK1 and parkin generate a carpet of short phosphoubiquitin chains to trigger mitophagy (Extended Data Fig. 10h ).
The ability of Lb pro to turn the ubiquitome into a GlyGly-modified proteome facilitates ubiquitination site and chain linkage analysis by reducing the background from cellular samples and by enabling new applications for well-established tools, including TUBE pull-down assays and anti-GlyGly antibodies. More importantly, Ub-clipping provides unprecedented and unbiased insights into ubiquitin chain architecture, which has largely remained inaccessible. Intact mass analysis of the Lb pro -generated monoubiquitin species reveals and quantifies relative amounts of, for example, branch-point ubiquitin, and can provide information on co-modified ubiquitin, such as the chain context of a phosphorylated ubiquitin. This will eventually help to model polyubiquitin architecture-the 'grammar' of the ubiquitin code-in greater detail, and reveal the regulatory potential of the vast number of independent polyubiquitin signals. Relative abundance (%) Relative abundance (%) 
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Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/ s41586-019-1482-y. . Ubiquitin E1, E2 and E3 enzymes, and PINK1 were purified as described previously 11, [36] [37] [38] [39] [40] [41] . Diubiquitin cleavage assays. Cleavage assays were performed according to ref. 42 by incubating 1.25 µM of each diubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63, Met1) with 10 µM Lb pro in reaction buffer (50 mM Tris pH 8.0, 50 mM NaCl, 2 mM dithiothreitol (DTT)). Reactions were incubated at 37 °C and quenched by adding LDS sample buffer. Samples were resolved on NuPAGE 4-12% Bis-Tris gels (Invitrogen) run in MES buffer, and silver stained. Kinetic cleavage measurements. Fluorescence polarization assays. Fluorescent substrate (0.1 µM of ubiquitin-Lys-Gly-5 carboxytetramethylrhodamine (TAMRA) or Lys63-diUb-fluorescein arsenical hairpin (FlAsH) was incubated with the indicated concentrations of enzyme in reaction buffer (50 mM Tris pH 8.0, 10 mM DTT, 0.05 mg ml −1 BSA). Measurements were performed with a PheraStar plate reader (BMG Labtech) using either the FlAsH optic module (λ ex = 485 nm, λ em = 520 nm) or the TAMRA optic module (λ ex = 540 nm, λ em = 590 nm). The reaction was carried out in a total volume of 20 µl at 25 °C in a black, roundbottom, non-binding surface 384-well plate (Greiner) and analysed every min over a time-course of 90 min. Raw data were background-corrected using a polarization time course from an uncleaved substrate. All experiments were performed as technical triplicates and data were analysed in Microsoft Excel and GraphPad Prism. Nonlinear curve fitting to extract a one-phase exponential decay constant was carried out without a constraint of the plateau position. Rate constants observed in two independent experiments were plotted against enzyme concentration, and the slope of a linear fit yielded the catalytic efficiencies corresponding to the reported k cat /K M ratio. Gel-based assays. Lys6/Lys48 branched triubiquitin substrate (10 µM) was incubated with varying enzyme concentrations (1.5, 1.125, 0.75 µM Lb pro or 0.25, 0.188, 0.125 µM Lb pro * ) in reaction buffer (50 mM Tris pH 8.0, 10 mM DTT). Samples were removed and quenched in DTT-containing LDS sample buffer every 2 min over a 10-min time course and resolved on NuPAGE 4-12% Bis-Tris gels (Invitrogen). Gels were Coomassie-stained (Instant Blue, Expedeon) and band intensities were quantified with ImageJ. Monoubiquitin band intensities were normalized to the substrate intensity and data from the linear portion of each time course were used to determine initial rates. The slope of a linear fit of initial rates observed in three independent experiments against enzyme concentration yielded catalytic efficiencies corresponding to the reported k cat /K M ratio. Mass spectrometric analysis of ubiquitin cleavage. Assays were performed similarly to diubiquitin cleavage assays but with a diubiquitin concentration of 10 µM. Reactions were incubated at 37 °C for 24 h and quenched with 50% acetonitrile (v/v), 0.1% formic acid (v/v). Ubiquitin was diluted to 1 pmol µl −1 in quenching solution before intact mass spectrometric analysis. Samples were injected at a flow rate of 5 µl min −1 and ionized using a heated electrospray ionization (HESI-II) source before being analysed with a Q Exactive Orbitrap mass analyser (Thermo Fisher Scientific). Ionization, data collection and deconvolution of spectra were performed exactly as described in ref. 11 . Ubiquitin chain assembly reactions. Assays were performed by mixing 25-50 µM ubiquitin, 100 nM mouse E1, 2.5-10 µM E2, 2.5-10 µM E3, 10 mM ATP in 40 mM Tris pH 7.4, 10 mM MgCl 2 , 0.6 mM DTT. In the AREL1 assembly reaction the buffer was supplemented with 10% (v/v) glycerol, 100 mM NaCl, and Tris pH 8.5 (instead of pH 7.4). Assembly reactions were incubated at 37 °C for 1 h, with the exception of UBE2S(∆C) (UBE2S lacking the C-terminal Lys-rich sequence) and AREL1, for which the reaction times were 16 h and 4 h, respectively. Ubiquitin and phosphoubiquitin chains were assembled using UBE2D3/cIAP1 assembly machinery according to ref.
Letter reSeArCH
25. Kaiser, S. E. et al. Protein standard absolute quantification (PSAQ) method for the measurement of cellular ubiquitin pools. Nat. Methods 8, 691-696 (2011
11
. Ser65-phosphorylated human parkin (pParkin) was purified as in ref. 41 . For parkin assembly reactions, pParkin (4 µM) was incubated for 2 h at 37 °C in the presence of human E1 (0.2 µM), UBE2L3 (2-4 µM as indicated), ubiquitin (15 µM) and, where indicated, Ser65-phosphorylated ubiquitin (1.5 µM) in reaction buffer (50 mM Tris, pH 8.5, 200 mM NaCl, 10 mM MgCl2, 10 mM ATP, 10 mM DTT). Staurosporine (10 µM) and Nb696 (0.8 µM) were added to inhibit kinase activity 43 . The assembly reactions were terminated by the addition of 2 mU of apyrase (Sigma-Aldrich) for 1 h at 37 °C. Lb pro treatment of in vitro assembly reactions. Ubiquitin chain assembly reactions were incubated with 10 µM Lb pro in 50 mM Tris pH 8.0, 10 mM DTT. The reactions were incubated at 37 °C and stopped by mixing with LDS sample buffer at the indicated time points. The protein samples were resolved on NuPAGE 4-12% Bis-Tris gels and visualized by anti-ubiquitin western blots (07-375, Millipore), silver staining (161-0481, Bio-Rad), or Coomassie staining using Instant Blue Coomassie SafeStain (Expedeon).
Western blot analysis. Protein from ubiquitin assembly reactions or whole-cell lysates was transferred to a nitrocellulose membrane. For additional visualization of monoubiquitin (for example, Fig. 3a) , the lower portion of the gel (below 14 kDa) was transferred instead to a PVDF membrane. Samples from Fig. 4e and Extended Data Fig. 10e were transferred to a PVDF membrane. Western blots were incubated at 4 °C in a 1:1,000 primary antibody dilution overnight in PBS-T + 5% (w/v) BSA and 1:5,000 secondary antibody dilution overnight in PBS-T + 5% (w/v) milk before being visualized by chemiluminescence. Primary antibodies used include anti-ubiquitin (07-375, Millipore), anti-pSer65 phosphoubiquitin (ABS1513-I, Millipore), anti-parkin (ab77924, Abcam) and anti-GlyGly (30-1000, Lucerna). The primary anti-ubiquitin antibody (NB300-130, Novus Biologicals) was used for western blots in Fig. 4e and Extended Data Fig. 10e . Secondary horseradishperoxidase-linked antibodies included anti-mouse and anti-rabbit (NXA931V and NA934V, GE Healthcare). AQUA MS. Following Lb pro cleavage and separation by SDS-PAGE, the molecular mass range surrounding monoubiquitin (5-10 kDa) was excised from the gel and diced into 1-mm 3 cubes with a scalpel. Quantitative ubiquitin linkage analysis using AQUA was performed according to ref. 11 . For in vitro parkin assembly reactions, AQUA analysis was performed on TUBE-purified chains. These samples were separated 2 cm into the gel before the lane was processed and analysed by AQUA MS. Intact mass spectrometry on ubiquitin from assembly reactions and quantification by protein deconvolution. Lb pro -treated assembly reactions were diluted to 1 µM ubiquitin with quenching solution (50% acetonitrile (v/v), 0.1% formic acid (v/v)). Samples were ionized using a heated electrospray ionization source (HESI-II, Thermo Fisher Scientific) at a flow rate of 5 µl min . Ionization settings were the same as those in ref.
. Data were collected on a Q Exactive at a resolution of 140,000 over a period of 1 min. Spectra were averaged and subsequently deconvoluted using the Xtract node of Thermo Xcalibur Qual Browser . All cell lines were routinely checked for mycoplasma contamination using the MycoAlert detection kit (Lonza) and confirmed negative for mycoplasma contamination. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) plus GlutaMAX (Gibco) supplemented with 10% (v/v) fetal calf serum and PenStrep (100 U ml −1 penicillin and streptomycin). Cell lines were grown to 90% confluency before lysate preparation. Cells were washed in PBS, collected and immediately frozen in liquid nitrogen. Protein extraction. Cell pellets were lysed in extraction buffer (50 mM Tris pH 8.0, 50 mM NaCl, 10 mM chloroacetamide, 5 mM EDTA, 1 mM PMSF, 0.1% (v/v) NP-40, 25 mM sucrose, 5% (v/v) glycerol, 4 M urea). To supplement lysis and shear DNA, lysates were sonicated using a microtip. Sonication settings were as follows: amplification 10%, 10 s on, 10 s off, total sonication time 1 min. The lysate was incubated on ice for 1 min and sonication was repeated. The lysate was pelleted at 21,000g, after which the supernatant was removed and total protein quantified with Bradford reagent (Bio-Rad Laboratories) using bovine γ-globulin as a standard. Generation of fluorescently labelled ubiquitin and diubiquitin. For maleimide labelling, ubiquitin containing a serine-to-cysteine mutation at residue 20 (ubiquitin(S20C)) or diubiquitin containing an S20C mutation in the distal moiety were used. Lys11-linked diubiquitin was assembled overnight using UBE2S(ΔC) 38 , with ubiquitin(K11R/S20C/K63R) as the distal moiety and ubiquitin(K63R) lacking the C terminus (ΔLRGG) as the proximal moiety, and purified by size-exclusion chromatography (HiLoad 16/60 Superdex 75, GE Healthcare). Lys48-linked diubiquitin was assembled for 90 min using Cdc34 44 , with ubiquitin(K6R/S20C/ K48R) as the distal moiety and ubiquitin(ΔLRGG) as the proximal moiety, and purified using cation-exchange chromatography (MonoS, GE Healthcare) followed by size-exclusion chromatography as above.
Before labelling, ubiquitin(S20C) and diubiquitin variants were first incubated in 2 mM β-mercaptoethanol-containing buffer for 45 min at 25 °C and then buffer-exchanged into 50 mM Tris, pH 7.4 using PD Spintrap G-25 (GE Healthcare). Variants were incubated with an approximately 6-fold excess of Alexa Fluor maleimide dye (Thermo Fisher Scientific; ubiquitin with Alexa Fluor 546 C 5 maleimide, Lys11-linked diubiquitin with Alexa Fluor 488 C 5 maleimide and Lys48-linked diubiquitin with Alexa Fluor 647 C 2 maleimide) at 25 °C overnight in Letter reSeArCH the dark. After the labelling step, ubiquitin variants were separated from unreacted dye using illustra NAP-10 columns (GE Healthcare) according to the manufacturer. Purification of total ubiquitin. All steps were performed at 4 °C unless stated otherwise. For purification of total ubiquitin, a single confluent 15-cm dish of cells was used per replicate. The cell pellet was resuspended in 300 µl of extraction buffer and processed as described above. To standardize the cleavage of ubiquitin chains by Lb pro , the final concentration of total protein was adjusted to 5 mg ml −1 using lysis buffer without urea; this typically reduced the final concentration of urea to around 1 M, a concentration at which Lb pro retains activity. Cell lysates were incubated with 100 µM Lb pro for 5 h at 37 °C. After incubation, samples were dialysed in ice-cold ultra-pure water overnight. Following dialysis, precipitated proteins were removed by centrifugation at 21,000g. The remaining, ubiquitin-containing fraction was subjected to gel filtration on a Superdex 75 3.2/300 gel filtration column using an ÄKTAmicro System (GE Healthcare). Fractions containing ubiquitin were identified by western blotting, concentrated and used for mass spectrometry.
To test for retention of ubiquitin ligase or deubiquitinase activity after dilution of the lysates in lysis buffer without urea, lysates were incubated with fluorescently labelled monoubiquitin (Alexa Fluor 546), Lys11-linked di-ubiquitin (Alexa Fluor 488) and Lys63-linked di-ubiquitin (Alexa Fluor 647), whereby the respective fluorophores are chemically attached to ubiquitin(S20C). Lysates (0.75 µg total protein per sample) were incubated with 90 ng of each fluorescent ubiquitin at 37 °C for the indicated times, with or without Lb pro , then run on NuPAGE 4-12% Bis-Tris gels. The emission of each fluorophore was measured using a Chemidoc MP (Bio-Rad) using the instrument's optimal exposure settings. Another exposure was taken at approximately three times the optimal exposure time to detect any lowly abundant forms. To test that the fluorescently modified ubiquitin species were still competent for assembly, 5 µM Alexa Fluor 546-labelled monoubiquitin was assembled using 0.1 µM human E1, 0.5 µM UBE2D3 and 0.5 µM TRAF6. Cleavage of each labelled diubiquitin was confirmed by treating 5 µM diubiquitin with 1 µM USP21 for 1 h at 37 °C. TUBE pull-down assays. A confluent 10-cm dish was used in each replicate experiment or, in the case of in vitro chain assemblies, 30 µl of the assembly reaction. For doxycycline-inducible parkin-expressing cell lines, cells were pre-treated with 0.1 µg ml −1 doxycycline for 16 h, followed by a 1-h treatment with 10 µM CCCP. All steps were performed at 4 °C unless stated otherwise. Frozen cell pellets were resuspended in 300 µl of TUBE lysis buffer (20 mM Na 2 HPO 4 , 20 mM NaH 2 PO 4 , 1% (v/v) NP-40, 2 mM EDTA, 1 mM DTT, 10 mM chloroacetamide, cOmplete EDTAfree Protease Inhibitor Cocktail (Roche) and PhosSTOP (Roche)) supplemented with 100 µg of GST 4× ubiquilin 1 TUBE 22 (15 µg for assembly reactions). Samples were incubated on ice for 20 min before centrifugation at 21,000g. The cleared lysate was incubated with 25 µl of pre-washed Glutathione Sepharose 4B resin (GE Healthcare). Samples were incubated on a rotating wheel for 2 h. Glutathione beads were washed three times with 500 µl PBS + 0.1% (v/v) Tween20 followed by a final wash with PBS. Enriched ubiquitin chains were incubated with 4 column volumes of 100 µM Lb pro * for 16 h at 37 °C. After Lb pro * cleavage, the supernatant containing ubiquitin species was removed for mass spectrometry sample preparation. Mitochondria isolation and enrichment of ubiquitinated proteins. For mitochondrial enrichment experiments, doxycycline-inducible parkin-expressing cell lines were used 10 . Before collection, cells were pre-treated for 16 h with 0.5 µM doxycycline, followed by a 2-h treatment with 0.5 µM doxycycline, and 10 µM oligomycin/4 µM antimycin A (OA). Mitochondria were isolated as previously described 45 , with minor modifications. Oligomycin/antimycin A-treated cells were resuspended in 20 mM HEPES (pH 7.6), 220 mM mannitol, 70 mM sucrose, 1 mM EDTA, supplemented with 1x cOmplete protease inhibitor (Roche) and 1x PhosStop (Roche). Following homogenization with a dounce homogenizer, samples were pelleted for 5 min at 1,000g at 4 °C. The post-nuclear supernatant was centrifuged for 10 min at 10,000g at 4 °C, to pellet the mitochondrial fraction. Further purification of ubiquitinated integral mitochondrial membrane proteins was achieved by treatment with sodium carbonate 33, 46 . For this, mitochondrial pellets were resuspended in 100 mM sodium carbonate, incubated at 4 °C for 30 min with occasional vortexing, and then centrifuged for 30 min at 21,000g at 4 °C. The pellets were resuspended in 50 mM Tris pH 7.4 and centrifuged for 30 min at 21,000g at 4 °C to remove residual sodium carbonate. Lb pro treatment of mitochondrial ubiquitin. Sodium carbonate-treated mitochondria were resuspended in 50 mM NaCl, 50 mM Tris (pH 8.0), 10 mM DTT containing 20 µM Lb pro * and incubated overnight at 37 °C. Where indicated, 10 pmol of 15 N-phosphoubiquitin was spiked into the sample to detect contaminating phosphatase activity. Membranes were pelleted at 21,000g for 30 min at 4 °C. The supernatant containing cleaved ubiquitin was further purified by perchloric acid extraction (see 'Preparation of TUBE-purified ubiquitin samples for mass spectrometry'). Preparation of TUBE-purified ubiquitin samples for mass spectrometry. After purification and Lb pro * cleavage, ubiquitin species were further purified by perchloric acid precipitation. After cleavage, perchloric acid was slowly added to a final concentration of 0.5% (v/v). After incubation for 10 min on ice, the samples were centrifuged at 21,000g in a pre-cooled microcentrifuge. This step retained all GlyGly-modified ubiquitin and GlyGly-modified phosphoubiquitin in the soluble fraction (data not shown). The supernatant was removed, placed in a pre-soaked Slide-A-Lyzer MINI 3.5 K MWCO (69550, Thermo Fisher Scientific) and dialysed in 50 mM Tris pH 7.4 for 4 h, and subsequently ultra-pure water for 16 h. Samples were then lyophilized and stored at −80 °C. LC-MS of intact ubiquitin from cells. Ubiquitin was resuspended in 15 µl of reconstitution buffer (5% (v/v) acetonitrile, 0.1% (v/v) formic acid). Insoluble material was removed by centrifugation. The supernatant was transferred to a glass vial and placed in the autosampler. Using a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific), 10 µl of the sample was loaded onto a C4 PepMap300 precolumn trap (Thermo Fisher Scientific) at a flow rate of 30 µl min −1
. Trapped proteins were eluted using an acetonitrile gradient (5-40%) over 45 min. Immediately before ionization, proteins were separated using an EASYSpray C4 reverse-phase column (Thermo Fisher Scientific). Proteins were analysed on a Q Exactive mass spectrometer (Thermo Fisher Scientific). Mass spectrometric analysis was performed using the following settings: resolution, 140,000; AGC target, 3E6; maximum injection time, 200 ms; scan range, 150-2,000 m/z. LC-MS quantification by peak integration. Raw files generated from LC-MS runs were analysed in Thermo Xcalibur Qual Browser version 2.2 (Thermo Fisher Scientific). The charge state of the ubiquitin species with the highest intensity, corresponding to z = +12 and the nominal mass-that is, the most naturally abundant 13 C isotope-within this charge state were used for quantification. The masses used for quantification are as follows: 705.22731 (unmodified), 714.73089 (1 × GG), and 724.23446 (2 × GG). The total ion current of each mass was integrated using a mass tolerance of 10 or 15 p.p.m. Additional Qual Browser settings included the following: Gaussian smoothing enabled (15 points) and a mass precision of five decimal places. Parallel reaction monitoring assays of branched ubiquitin. Branched ubiquitin molecules (that is, ubiquitin with the addition of two GlyGly motifs and minus the C-terminal GlyGly amino acids) were isolated and fragmented in a Q Exactive mass spectrometer (Thermo Fisher Scientific). Ubiquitin with a mass-to-charge ratio of 724.24 was isolated in the quadrupole using an isolation window of 2 m/z and fragmented using the following settings: resolution, 17,500; AGC target, 1E5; maximum injection time, 120 ms; normalized collision energy, 28. Fragment ions were inspected manually using Thermo Xcalibur Qual Browser version 2.2, and assigned using Expert System 47 . Shotgun proteomics. Discovery proteomics assays were performed according to ref. 48 . In brief, a Top10 analysis was performed on peptides generated from the purified monoubiquitin band, and precursor masses were screened using the following settings: mass range, 200-2,000 m/z; resolution, 70,000; automatic gain control target (AGC), 1 × 10 6 ; maximum ion trap time, 250 ms; scan-type, positive. Data-dependent settings include the following: resolution, 17,500; AGC target, 5 × 10 4 ; maximum ion trap time, 80 ms; isolation window, 2.0 m/z; collision energy, 28.0; data type, centroid; exclusion of unassigned charge states and masses with a charge state of 1. Dynamic exclusion enabled, 30 s. Raw files were searched and spectra assigned using SEQUEST against a human genome database (UniProt) in Proteome Discoverer (Thermo Scientific) with a false-discovery rate of 1%. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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